Interpharm Holdings Inc - Current report filing (8-K)
16 Abril 2008 - 4:25PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported)
April
16, 2008
Interpharm
Holdings, Inc.
(Exact
name of Registrant as specified in charter)
|
Delaware
|
0-22710
|
13-3673965
|
|
(State
or other jurisdic-
|
(Commission
|
(IRS
Employer
|
|
tion
of incorporation)
|
File
Number)
|
Identification
No.)
|
|
|
|
|
|
|
|
|
|
75
Adams Avenue, Hauppauge, New York
|
11788
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code:
(631)
952 0214
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
3.01
|
Notice
of Failure to Satisfy a Continued Listing
Rule
|
On
April
10, 2008, Interpharm Holdings, Inc. (the “Company”) received notice from the
American Stock Exchange (“AMEX”) that the Company is not in compliance with the
following continuing listing standards contained in the AMEX Company
Guide:
|
|
1.
|
Section
1003(a)(i) because of stockholders equity less than $2,000,000 and
losses
from continuing operations and net losses in two out of its three
most
recent fiscal years;
|
|
|
2.
|
Section
1003(a)(ii) because of stockholders equity of less than $4,000,000
and
losses from continuing operations and net losses in three out of
its four
most recent fiscal years; and
|
|
|
3.
|
Section
1003(a)(iv) because of sustained losses.
|
In
response to the AMEX letter, the Company plans to submit a plan of operations
demonstrating how it will regain compliance with AMEX continuing listing
standards.
|
Item
5.02
|
Departure
of Directors or principal Officers; Election of Directors, Appointment
of
Principal Officers
|
On
April
10, 2008, the Company’s Board of Directors accepted the resignation of the
Company’s Chief Executive Officer, Cameron Reid. Mr. Reid is continuing in his
service to the Company as a consultant assisting in the management of the
Company’s business.
|
Item
9.01
|
Financial
Statements and Exhibits
|
|
Exhibit
99.1
|
Press
release, dated April 16, 2008.
|
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
INTERPHARM
HOLDINGS, INC.
|
|
|
|
|
|
April
16, 2008
|
By:
|
/s/
Peter Giallorenzo.
|
|
|
|
Peter
Giallorenzo
|
|
|
|
Chief
Financial Officer and
|
|
|
|
Chief
Operating Officer
|
Interpharm (AMEX:IPA)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Interpharm (AMEX:IPA)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
